Master Alliance Provisions Guide (MAPGuide)

US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement

  • Information & materials sharing | Dissemination of Results

9.0 Publication Policy 

9.1 Publication of Clinical Data Related to the Trial

Any publication or presentation related to the clinical trial must be submitted to Sanofi Pasteur (SP) [redacted content] for review before submission of the manuscript. After publication of the results of the trial, any participating center may publish or otherwise use its own data provided that any publication of data from the trial gives recognition to the trial group. In addition, SP [redacted content] shall be offered an association with all such publications, it being understood that SP [redacted content] are each entitled to refuse the association.

SP [redacted content] must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding these trials at least 30 days prior to submission for publication / presentation. Any information identified by SP [redacted content] as confidential must be deleted prior to submission, it being understood that the results of this trial are not to be considered confidential, provided that any publication of data from the trial gives recognition to the trial group. In addition, SP [redacted content] shall be offered an association with all such publications, it being understood that SP [redacted content] are each entitled to refuse the association. 

9.2 Publication of Nonclinical Subject Data

Publication of any nonclinical Subject Data shall be prohibited without the express permission of Sanofi Pasteur [redacted content].